| Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction FC Brownfoot, R Hastie, NJ Hannan, P Cannon, L Tuohey, LJ Parry, ... American journal of obstetrics and gynecology 214 (3), 356. e1-356. e15, 2016 | 243 | 2016 |
| Effects of pravastatin on human placenta, endothelium, and women with severe preeclampsia FC Brownfoot, S Tong, NJ Hannan, NK Binder, SP Walker, P Cannon, ... Hypertension 66 (3), 687-697, 2015 | 183 | 2015 |
| Proton pump inhibitors decrease soluble fms-like tyrosine kinase-1 and soluble endoglin secretion, decrease hypertension, and rescue endothelial dysfunction K Onda, S Tong, S Beard, N Binder, M Muto, SN Senadheera, L Parry, ... Hypertension 69 (3), 457-468, 2017 | 141 | 2017 |
| The effect of pre-existing maternal obesity and diabetes on placental mitochondrial content and electron transport chain activity R Hastie, M Lappas Placenta 35 (9), 673-683, 2014 | 115 | 2014 |
| Aspirin use during pregnancy and the risk of bleeding complications: a Swedish population-based cohort study R Hastie, S Tong, AK Wikström, A Sandström, S Hesselman, L Bergman American Journal of Obstetrics and Gynecology 224 (1), 95. e1-95. e12, 2021 | 114 | 2021 |
| Placental-specific sFLT-1 e15a protein is increased in preeclampsia, antagonizes vascular endothelial growth factor signaling, and has antiangiogenic activity KR Palmer, TJ Kaitu’u-Lino, R Hastie, NJ Hannan, L Ye, N Binder, ... Hypertension 66 (6), 1251-1259, 2015 | 99 | 2015 |
| Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia S Tong, J Tu’uhevaha, R Hastie, F Brownfoot, C Cluver, N Hannan American journal of obstetrics and gynecology 226 (2), S1157-S1170, 2022 | 74 | 2022 |
| Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial … FC Brownfoot, S Tong, NJ Hannan, R Hastie, P Cannon, TJ Kaitu’u-Lino BMC pregnancy and childbirth 16, 1-8, 2016 | 71 | 2016 |
| Characterization of protocols for primary trophoblast purification, optimized for functional investigation of sFlt-1 and soluble endoglin J Tu’uhevaha, S Tong, S Beard, R Hastie, L Tuohey, F Brownfoot, K Onda, ... Pregnancy Hypertension: An International Journal of Women's Cardiovascular …, 2014 | 64 | 2014 |
| EGFR (epidermal growth factor receptor) signaling and the mitochondria regulate sFlt-1 (soluble FMS-like tyrosine kinase-1) secretion R Hastie, FC Brownfoot, N Pritchard, NJ Hannan, P Cannon, V Nguyen, ... Hypertension 73 (3), 659-670, 2019 | 61 | 2019 |
| Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction–implications for treating preeclampsia TJ Kaitu’u-Lino, FC Brownfoot, S Beard, P Cannon, R Hastie, TV Nguyen, ... PLoS One 13 (2), e0188845, 2018 | 54 | 2018 |
| Prevalence of perinatal depression in low-and middle-income countries: a systematic review and meta-analysis AR Mitchell, H Gordon, A Lindquist, SP Walker, CSE Homer, A Middleton, ... JAMA psychiatry 80 (5), 425-431, 2023 | 47 | 2023 |
| Circulating SPINT1 is a biomarker of pregnancies with poor placental function and fetal growth restriction TJ Kaitu’u-Lino, TM MacDonald, P Cannon, TV Nguyen, RJ Hiscock, ... Nature communications 11 (1), 2411, 2020 | 45 | 2020 |
| Sulfasalazine reduces placental secretion of antiangiogenic factors, up-regulates the secretion of placental growth factor and rescues endothelial dysfunction FC Brownfoot, NJ Hannan, P Cannon, V Nguyen, R Hastie, LJ Parry, ... EBioMedicine 41, 636-648, 2019 | 44 | 2019 |
| Heme oxygenase-1 is not decreased in preeclamptic placenta and does not negatively regulate placental soluble fms-like tyrosine kinase-1 or soluble endoglin secretion S Tong, TJ Kaitu’u-Lino, K Onda, S Beard, R Hastie, NK Binder, C Cluver, ... Hypertension 66 (5), 1073-1081, 2015 | 39 | 2015 |
| Identifying late-onset fetal growth restriction by measuring circulating placental RNA in the maternal blood at 28 weeks’ gestation CL Whitehead, H McNamara, SP Walker, M Alexiadis, PJ Fuller, ... American journal of obstetrics and gynecology 214 (4), 521. e1-521. e8, 2016 | 36 | 2016 |
| Proton pump inhibitors and preeclampsia risk among 157 720 women: a Swedish population register–based cohort study R Hastie, L Bergman, CA Cluver, A Wikman, NJ Hannan, SP Walker, ... Hypertension 73 (5), 1097-1103, 2019 | 34 | 2019 |
| Activating transcription factor 3 is reduced in preeclamptic placentas and negatively regulates sFlt-1 (soluble fms-like tyrosine kinase 1), soluble endoglin, and … TJ Kaitu’u-Lino, FC Brownfoot, R Hastie, A Chand, P Cannon, M Deo, ... Hypertension 70 (5), 1014-1024, 2017 | 34 | 2017 |
| YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia FC Brownfoot, S Tong, NJ Hannan, R Hastie, P Cannon, L Tuohey, ... Molecular and cellular endocrinology 413, 202-208, 2015 | 32 | 2015 |
| Circulating growth differentiation factor 15 is increased preceding preeclampsia diagnosis: implications as a disease biomarker T Cruickshank, TM MacDonald, SP Walker, E Keenan, K Dane, ... Journal of the American Heart Association 10 (16), e020302, 2021 | 26 | 2021 |
